Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Sakkaraiappan Ramalingam & Chandra P Belani. (2004) Paclitaxel for non-small cell lung cancer. Expert Opinion on Pharmacotherapy 5:8, pages 1771-1780.
Read now
Read now
Articles from other publishers (20)
Carolina G. Vital, Raul C. Maranhão, Fatima R. Freitas, Brigitte M. Van Eyll & Silvia R. Graziani. (2022) Use of paclitaxel carried in lipid core nanoparticles in patients with late-stage solid cancers with bone metastases: Lack of toxicity and therapeutic benefits. Journal of Bone Oncology 34, pages 100431.
Crossref
Crossref
Al Hassan Kyakulaga, Farrukh Aqil, Radha Munagala & Ramesh C. Gupta. (2020) Synergistic combinations of paclitaxel and withaferin A against human non-small cell lung cancer cells. Oncotarget 11:16, pages 1399-1416.
Crossref
Crossref
Anran Song, Jianbin Zhang, Yang Ge, Changyuan Wang, Qiang Meng, Zeyao Tang, Jinyong Peng, Kexin Liu, Yanxia Li & Xiaodong Ma. (2017) C -2 ( E )-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR T790M mutant. Bioorganic & Medicinal Chemistry 25:10, pages 2724-2729.
Crossref
Crossref
C. Khanna, M. Rosenberg & D. M. Vail. (2015) A Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs. Journal of Veterinary Internal Medicine 29:4, pages 1006-1012.
Crossref
Crossref
Joel L. Weissfeld, Brenda Diergaarde, Tomoko Nukui, Shama Buch, Arjun Pennathur, Mark A. Socinski, Jill M. Siegfried & Marjorie Romkes. (2014) Inherited Variation in the ATP-Binding Cassette Transporter ABCB1 and Survival after Chemotherapy for Stage III–IV Lung Cancer. Journal of Thoracic Oncology 9:9, pages 1264-1271.
Crossref
Crossref
Monika Joshi, Xin Liu & Chandra P. Belani. (2014) Taxanes, past, present, and future impact on non-small cell lung cancer. Anti-Cancer Drugs 25:5, pages 571-583.
Crossref
Crossref
Huiyan Niu, Jiahe Wang, Hui Li & Ping He. (2011) Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells. Journal of Experimental & Clinical Cancer Research 30:1.
Crossref
Crossref
Suresh S. Ramalingam, R. Donald Harvey, Nabil Saba, Taofeek K. Owonikoko, John Kauh, Dong M. Shin, Shi-Yong Sun, Sandra Strychor, Mourad Tighiouart, Merrill J. Egorin, Haian Fu & Fadlo R. Khuri. (2010) Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer 116:16, pages 3903-3909.
Crossref
Crossref
David O Holtz, Robert T Krafty, Alisha Mohamed-Hadley, Lin Zhang, Ioannis Alagkiozidis, Benjamin Leiby, Wensheng Guo, Phyllis A Gimotty & George Coukos. (2008) Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. Journal of Translational Medicine 6:1.
Crossref
Crossref
Suresh Ramalingam, Michael C. Perry, Renato V. La Rocca, David Rinaldi, Preston S. Gable, William J. Tester & Chandra P. Belani. (2008) Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer 113:3, pages 542-546.
Crossref
Crossref
Suresh S. Ramalingam, Merrill J. Egorin, Ramesh K. Ramanathan, Scot C. Remick, Rachel P. Sikorski, Theodore F. Lagattuta, Gurkamal S. Chatta, David M. Friedland, Ronald G. Stoller, Douglas M. Potter, S. Percy Ivy & Chandra P. Belani. (2008) A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies. Clinical Cancer Research 14:11, pages 3456-3461.
Crossref
Crossref
Jue Wang, Yong Fang Kuo, Jean Freeman, Avi B. Markowitz & James S. Goodwin. (2008) Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer. Cancer 112:2, pages 382-390.
Crossref
Crossref
Hua Zhong, Baohui Han, Irina L. Tourkova, Anna Lokshin, Alan Rosenbloom, Michael R. Shurin & Galina V. Shurin. (2007) Low-Dose Paclitaxel Prior to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer Growth. Clinical Cancer Research 13:18, pages 5455-5462.
Crossref
Crossref
Carmen I. Calfa, Joseph D. Rosenblatt, Hyun-Mi Cho, Keith Webster & Seung-Uon Shin. (2006) Antibodies and antibody-fusion proteins as anti-angiogenic, anti-tumor agents. Update on Cancer Therapeutics 1:2, pages 159-173.
Crossref
Crossref
Athanassios Argiris, Victoria Kut, Lynn Luong & Michael J. Avram. (2005) Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer. Investigational New Drugs 24:3, pages 203-212.
Crossref
Crossref
Suresh Ramalingam, John Barstis, Michael C. Perry, Renato V. La Rocca, Sreenivasa R. Nattam, David Rinaldi, Ray Clark, Glenn M. Mills & Chandra P. Belani. (2006) Treatment of Elderly Non–small Cell Lung Cancer Patients with Three Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomized Trial. Journal of Thoracic Oncology 1:3, pages 240-244.
Crossref
Crossref
Ramesh K. Ramanathan, Sakkaraiappan Ramalingam, Merrill J. Egorin, Chandra P. Belani, Douglas M. Potter, Marwan Fakih, Laura L. Jung, Sandra Strychor, Samuel A. Jacobs, David M. Friedland, Dong M. Shin, Gurkamal S. Chatta, Susan Tutchko & William C. Zamboni. (2004) Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology 55:4, pages 354-360.
Crossref
Crossref
M Harries, A O'Donnell, M Scurr, S Reade, C Cole, I Judson, A Greystoke, C Twelves & S Kaye. (2004) Phase I/II study of DHA–paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. British Journal of Cancer 91:9, pages 1651-1655.
Crossref
Crossref
A Argiris, M Liptay, M LaCombe, M Marymont, M.S Kies, S Sundaresan & G Masters. (2004) A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer. Lung Cancer 45:2, pages 243-253.
Crossref
Crossref
Sakkaraiappan Ramalingam & Chandra P Belani. (2004) Basic treatment considerations: chemotherapy. Hematology/Oncology Clinics of North America 18:1, pages 13-28.
Crossref
Crossref